Anne A. Gershon | |
---|---|
Nationality | American |
Alma mater | Smith College (BsC) Cornell University (MD) |
Known for | Work on chickenpox |
Spouse | Michael D. Gershon |
Awards | Albert B. Sabin Gold Medal (2013) Maxwell Finland Award (2019) |
Scientific career | |
Fields | Pediatric infectious disease |
Institutions | Columbia University |
Anne Gershon is an infectious disease researcher and professor of pediatrics at Columbia University. She is best known for her work on the varicella-zoster virus, the causative agent for chickenpox. [1] In the 1970s, she ran clinical trials for the varicella vaccine which showed that the vaccine was safe for children with leukemia. She also developed the first sensitive test for chickenpox. [2]
Gershon studied pre-medicine at Smith College and graduated in 1960. [3] She completed her medical degree at Cornell Medical School and her residency at New York Hospital. [4] While in New York, Gershon studied the herpes simplex virus in infants. [5]
After Michiaki Takahasi developed a vaccine against variella in the late 1960s, [6] Gershon organized the Varicella Vaccine Collaborative Study Group to study both the safety and efficacy of this vaccine. [2] This group, funded by the NIH, showed that the varicella vaccine was safe even for children who were in remission from leukemia. [7] In 1991, the group published "The Incidence of Zoster after Immunization with Live Attenuated Varicella Vaccine -- A Study in Children with Leukemia," in the New England Journal of Medicine. They showed that leukemic children who were vaccinated against varicella had lower rates of later varicella infection than children who were naturally infected. [8]
In 2000, Gershon, along with Ann M. Arvin, published Varicella-zoster virus: virology and clinical management. [9]
She has stated that her decision to study pediatrics was because it was "essentially the only field open to women at the time." [2]
In 1993, Gershon was awarded an honorary Doctorate of Science from Smith College. [1]
From 2008-2009, Gershon was the president of the Infectious Diseases Society of America. [1]
In 2013, Gershon was awarded the Albert B. Sabin Gold Medal in recognition of her research that led to public acceptance of the chickenpox vaccine. [10]
In 2019, Gershon was awarded the Maxwell Finland Award for Scientific Research. [11]
Anne Gershon is married to Michael D. Gershon. [2] Her father was a doctor, and she has stated that she wanted to pursue a similar career. [3] She has also cited her personal experiences with infectious diseases, including toxoplasmosis and mononucleosis, as her reason to study vaccinology. [2]
Varicella zoster virus (VZV), also known as human herpesvirus 3 or Human alphaherpesvirus 3 (taxonomically), is one of nine known herpes viruses that can infect humans. It causes chickenpox (varicella) commonly affecting children and young adults, and shingles in adults but rarely in children. As a late complication of VZV infection, Ramsay Hunt syndrome type 2 may develop in rare cases. VZV infections are species-specific to humans. The virus can survive in external environments for a few hours.
Shingles, also known as herpes zoster, is a viral disease characterized by a painful skin rash with blisters in a localized area. Typically the rash occurs in a single, wide mark either on the left or right side of the body or face. Two to four days before the rash occurs there may be tingling or local pain in the area. Other common symptoms are fever, headache, and tiredness. The rash usually heals within two to four weeks; however, some people develop ongoing nerve pain which can last for months or years, a condition called postherpetic neuralgia (PHN). In those with poor immune function the rash may occur widely. If the rash involves the eye, vision loss may occur.
Postherpetic neuralgia (PHN) is neuropathic pain that occurs due to damage to a peripheral nerve caused by the reactivation of the varicella zoster virus. PHN is defined as pain in a dermatomal distribution that lasts for at least 90 days after an outbreak of herpes zoster. Several types of pain may occur with PHN including continuous burning pain, episodes of severe shooting or electric-like pain, and a heightened sensitivity to gentle touch which would not otherwise cause pain or to painful stimuli. Abnormal sensations and itching may also occur.
Valaciclovir, also spelled valacyclovir, is an antiviral medication used to treat outbreaks of herpes simplex or herpes zoster (shingles). It is also used to prevent cytomegalovirus following a kidney transplant in high risk cases. It is taken by mouth.
Viral pneumonia is a pneumonia caused by a virus. Pneumonia is an infection that causes inflammation in one or both of the lungs. The pulmonary alveoli fill with fluid or pus making it difficult to breathe. Pneumonia can be caused by bacteria, viruses, fungi or parasites. Viruses are the most common cause of pneumonia in children, while in adults bacteria are a more common cause.
A vertically transmitted infection is an infection caused by pathogenic bacteria or viruses that use mother-to-child transmission, that is, transmission directly from the mother to an embryo, fetus, or baby during pregnancy or childbirth. It can occur when the mother has a pre-existing disease or becomes infected during pregnancy. Nutritional deficiencies may exacerbate the risks of perinatal infections. Vertical transmission is important for the mathematical modelling of infectious diseases, especially for diseases of animals with large litter sizes, as it causes a wave of new infectious individuals.
Brivudine is an antiviral drug used in the treatment of herpes zoster ("shingles"). Like other antivirals, it acts by inhibiting replication of the target virus.
The MMRV vaccine is a combination vaccine which combines the attenuated virus measles, mumps, rubella, and varicella (chickenpox). The MMRV vaccine has similar immunogenicity and overall safety profiles to the MMR vaccine administered with or without the varicella vaccine. The MMRV vaccine is typically given to children between one and two years of age.
A zoster vaccine is a vaccine that reduces the incidence of herpes zoster (shingles), a disease caused by reactivation of the varicella zoster virus, which is also responsible for chickenpox. Shingles provokes a painful rash with blisters, and can be followed by chronic pain, as well as other complications. Older people are more often affected, as are people with weakened immune systems (immunosuppression). Both shingles and postherpetic neuralgia can be prevented by vaccination.
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine are more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin. Another vaccine, known as zoster vaccine, is used to prevent diseases caused by the same virus – the varicella zoster virus.
Mollaret's meningitis is a recurrent or chronic inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges. Since Mollaret's meningitis is a recurrent, benign (non-cancerous), aseptic meningitis, it is also referred to as benign recurrent lymphocytic meningitis. It was named for Pierre Mollaret, the French neurologist who first described it in 1944.
Chickenpox, also known as varicella, is a highly contagious, vaccine-preventable disease caused by the initial infection with varicella zoster virus (VZV), a member of the herpesvirus family. The disease results in a characteristic skin rash that forms small, itchy blisters, which eventually scab over. It usually starts on the chest, back, and face. It then spreads to the rest of the body. The rash and other symptoms, such as fever, tiredness, and headaches, usually last five to seven days. Complications may occasionally include pneumonia, inflammation of the brain, and bacterial skin infections. The disease is usually more severe in adults than in children.
Ann M. Arvin is an American pediatrician and microbiologist. She is the Lucile Salter Packard Professor of Pediatrics and Professor of Microbiology & Immunology Emerita at Stanford University. Arvin is a specialist of the Varicella zoster virus (VZV) and a prominent national figure in health. Arvin is currently the chief of the infectious diseases division of pediatrics at the Lucile Packard Children's Hospital, as well as the former Stanford's Vice Provost and Dean of Research.
In medicine, varicella zoster virus globulin, VZV antibodies, zoster immunoglobulin (ZIG), varicella zoster immune globulin, is an immune system medication that is used mostly for immunosuppressed patients who have been or may be exposed to the varicella zoster virus (VZV).
Congenital varicella syndrome is a rare disease resulting from Varicella Zoster virus (VZV) infection during the period of gestation. Viremia during the primary infection can result in transplacental transmission of the infection to the developing fetus. An estimated 25% of fetuses get infected with varicella infection when mother has a varicella infection during the pregnancy but the risk of developing congenital varicella syndrome is around 2%, therefore majority of the outcomes are normal newborns. Patients with primary infection before 20 weeks of gestation are at a higher risk of developing the severe form of infection, affecting the eyes, limbs, skin and the central nervous system. Diagnosis requires a documented history of primary infection in the mother and serial ultrasound demonstrating features suggestive of congenital varicella syndrome. There is no definitive treatment, termination of pregnancy in fetuses with severe features is recommended. Vaccination to prevent maternal varicella infection and proper counseling to avoid contact with infected people are important for the management options to reduce the incidence of congenital varicella syndrome.
Michiaki Takahashi was a Japanese virologist, best known for inventing the first chickenpox vaccine. He developed the "Oka" vaccine by producing v-Oka, a live-attenuated virus strain of varicella zoster virus.
Stephen E. Straus was an American physician, immunologist, virologist and science administrator. He is particularly known for his research into human herpesviruses and chronic fatigue syndrome, and for his discovery of the autoimmune lymphoproliferative syndrome genetic disorder. He headed the Laboratory of Clinical Investigation of the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), and served as the founding director of the NIH's National Center for Complementary and Alternative Medicine.
Judith Breuer is a British virologist who is professor of virology and director of the Pathogen Genomics Unit at University College London. She was elected a Fellow of the Academy of Medical Sciences in 2019. Breuer is part of the United Kingdom genome sequencing team that looks to map the spread of the coronavirus disease 2019.
Live recombinant vaccines are biological preparations that stimulate immune responses to a pathogen through the use of genetically modified live bacteria or viruses. These live pathogens are biologically engineered to express exogenous antigens in the cytoplasm of target cells, thereby triggering immune responses. This form of vaccine combines the beneficial features of attenuated and recombinant vaccines, providing the long-lasting immunity of attenuated vaccines’ with recombinant vaccines’ genetically engineered precision and safety.